ClinicalTrials.gg
WithdrawnNCT02640833Updated Jul 26, 2016

A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

A Phase 1 interventional study of Duvelisib and Venetoclax in Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and Non-Hodgkin Lymphoma, sponsored by AbbVie. Withdrawn at 10 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2016-07-26.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Study Stopped

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing duvelisib in Leukemia, Lymphocytic, Chronic, B-Cell — none open to participants now, 2 under way, none of them phase 3. duvelisib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
10th of 12
0 · median 11
Started
2016
the only one that year
Phase 1
4 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
1 of 12
AbbVie

Among the 12 studies testing duvelisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 10th largest by enrollment, is the only one that started in 2016, is one of 4 in phase 1, and was the 7th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

None of the 12 studies testing duvelisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →

About duvelisib

duvelisib: first FDA approval 2018 (COPIKTRA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing duvelisib in Leukemia, Lymphocytic, Chronic, B-Cell as a file.
02

Study summary

This study is designed to assess the safety, pharmacokinetics, drug-drug interactions, and determine the recommended Phase 2 doses of co administered Duvelisib and Venetoclax in participants with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or indolent or aggressive non-Hodgkin lymphoma, who have not previously received a Bcl-2 or Phosphoinositide 3-kinase (PI3K) inhibitor. The Phase 2 portion of the study will preliminarily evaluate efficacy, and expand the toxicity evaluation.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Non-Hodgkin Lymphoma

Keywords

  • Refractory Lymphoma
  • Relapsed Leukemia
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: -

Subject must have either • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (for Waves 2 or 3)

  • Subject has evaluable disease and requires treatment in the opinion of the investigator.
  • Subject must have relapsed following or be refractory to ≥ 1 standard treatments such as fludarabine based regimens (F, FC, FR, FCR), alkylator (chlorambucil, bendamustine) based regimens, or Bruton's Tyrosine Kinase inhibitor (Ibrutinib).

Or

  • Relapsed or refractory indolent Non-Hodgkin Lymphoma or aggressive Non-Hodgkin Lymphoma (for Waves 1, 2, or 3, unless otherwise indicated)
  • Subject must have documented diagnosis of a Follicular Lymphoma or Marginal Zone Lymphoma.
  • Subject must have histologically documented diagnosis of a Diffuse Large B-cell Lymphoma (excluding Richter's Transformation), Non-cutaneous T-Cell Lymphoma, or Mantle Cell Lymphoma (MCL) (MCL Wave 3 only)
  • Subject has evaluable disease and requires treatment in the opinion of the investigator.
  • Subject must have relapsed following or be refractory to ≥ 1 standard treatments such as R-CHOP, R-CVP, bendamustine, lenalidomide-rituximab, or fludarabine-based regimens.

    • Subject has an (ECOG) performance score of less than or equal to 2.
    • Subject must have adequate bone marrow independent of growth factor support per local laboratory reference range at Screening.
    • Subject must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening.
    • NHL subjects who have a history of an stem cell transplant (e.g., bone marrow) must be > 6 months post-transplant (prior to the first dose of study drug) and must not require any growth factor support.

Exclusion Criteria:

  • Subject has been previously treated with a Bcl-2 or PI3K inhibitor.
  • Subject is a candidate to receive another therapy approved for usage by the local Health Authority.
  • Subject is appropriate for a stem cell transplant or has undergone an allogeneic stem cell transplant.
  • Subject has received any of the following within 14 days or 5 drug half-lives (whichever is shortest) prior to the first dose of duvelisib or venetoclax, or has not recovered to less than Grade 2 adverse effect(s)/toxicity(s) of the previous therapy:

    • Any anti-cancer therapy including chemotherapy or radiotherapy;
    • therapy, including targeted small molecule agents.
  • Subject has received biologic agents (e.g., monoclonal antibodies) for anti-neoplastic treatment within 30 days prior to first dose of duvelisib or venetoclax.
  • Subject has received live or within 6 weeks prior to first dose of duvelisib or venetoclax.
  • Subject has received the following within 7 days prior to the first dose of duvelisib or venetoclax:

    • therapy for anti-neoplastic treatment;
    • Strong and Moderate inhibitors;
    • Strong and Moderate CYP3A inducers;
    • Chronic , other than corticosteroids given at daily dose \< 20 mg prednisone equivalent for ITP or AIHA.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Duvelisib+Venetoclax

    Drug: Duvelisib · Drug: Venetoclax

Interventions

  • Duvelisib will be taken continuously. This is a defining dose study, therefore the dose of Duvelisib may change.

  • Venetoclax will be taken continuously. This is a defining dose study, therefore the dose of Venetoclax will change.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    Participants will be monitored for clinical and laboratory evidence of adverse events throughout the study.

    Time frame: From participant's first dose until 30 days after participant's last dose of study drug; up to 2 years following last participant first dose

  2. Maximum observed plasma concentration (Cmax) of duvelisib

    The highest concentration that a drug achieves in the blood after administration in a dosing interval.

    Time frame: Blood samples will be taken at 0 (pre-dose) 1,2,4,6,8,10 and 12 hours post-dose on Cycle 1 Day 14 and Day 22 for second and third dose levels.

  3. Maximum observed plasma concentration (Cmax) of venetoclax

    The highest concentration that a drug achieves in the blood after administration in a dosing interval.

    Time frame: Blood samples will be taken at 0 (pre-dose) 1,2,4,6,8,10, 12 and 24 hours post-dose on Cycle 1 Days 7 and 14, and Day 22 for second and third dose levels.

  4. Time to maximum observed plasma concentration (Tmax) of duvelisib

    The time at which the maximum plasma concentration (Cmax) is observed.

    Time frame: Blood samples will be taken at 0 (pre-dose) 1,2,4,6,8,10 and 12 hours post-dose on Cycle 1 Day 14 and Day 22 for second and third dose levels.

  5. Time to maximum observed plasma concentration (Tmax) of venetoclax

    The time at which the maximum plasma concentration (Cmax) is observed.

    Time frame: Blood samples will be taken at 0 (pre-dose) 1,2,4,6,8,10,12 and 24 hours post-dose on Cycle 1 Days 7 and 14, and Day 22 for second and third dose levels.

  6. Area under the plasma concentration-time curve from time 0 to 12 hours post-dose (AUC12) of duvelisib

    The area under the plasma concentration-time curve over a 12-hour dose interval

    Time frame: Blood samples will be taken at 0 (pre-dose) 1,2,4,6,8,10 and 12 hours post-dose on Cycle 1 Day 14 and Day 22 for second and third dose levels.

  7. Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC24) of venetoclax

    The area under the plasma concentration-time curve over a 24-hour dose interval

    Time frame: Blood samples will be taken at 0 (pre-dose) 1,2,4,6,8,10,12 and 24 hours post-dose on Cycle 1 Days 7 and 14, and Day 22 for second and third dose levels.

  8. Recommended phase two dose (RPTD) of Duvelisib in combination with venetoclax

    Time frame: Minimum first cycle of dosing (28 days)

  9. Recommended phase two dose (RPTD) of Venetoclax in combination with duvelisib

    Time frame: Minimum first cycle of dosing (28 days)

Secondary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival will be defined as the number of days from the date of study drug start to the date of documented disease progression, relapse of death due to any cause whichever occurs first.

    Time frame: Measured up to 2 years after the last participant has enrolled in the study

  2. Overall Response Rate (ORR)

    Overall response rate will be defined as the proportion of participants who achieve a partial remission or better.

    Time frame: Measured up to 2 years after the last participant has enrolled in the study

  3. Time to Tumor Progression (TTP)

    Time to tumor progression is defined as the number of days from the date of study drug start to the date of the first documented disease progression or relapse.

    Time frame: Measured up to 2 years after the last participant has enrolled in the study

  4. Duration of Response (DOR)

    Duration of response is defined as the number of days from the date of documented first response of partial remission or better to the date of documented disease progression/relapse or death due to the disease whichever occurs first

    Time frame: Measured up to 2 years after the last participant has enrolled in the study

07

Study locations

10 sites
  • Site Reference ID/Investigator# 145677
    Tucson, Arizona 85724-5024, United States
  • Site Reference ID/Investigator# 147922
    Chicago, Illinois 60611, United States
  • Site Reference ID/Investigator# 148562
    Harvey, Illinois 60426, United States
  • Site Reference ID/Investigator# 148561
    Goshen, Indiana 46526, United States
  • Site Reference ID/Investigator# 145674
    Baltimore, Maryland 21287, United States
  • Site Reference ID/Investigator# 145145
    Boston, Massachusetts 02215, United States
  • Site Reference ID/Investigator# 148010
    Detroit, Michigan 48202, United States
  • Site Reference ID/Investigator# 147747
    St. Louis, Missouri 63110, United States
  • Site Reference ID/Investigator# 145146
    Lebanon, New Hampshire 03756, United States
  • Site Reference ID/Investigator# 148559
    Greenville, South Carolina 29605, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Jan 2020 and a completion of Feb 2021. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2015
First posted
Dec 29, 2015
Start
Jul 2016
Primary completionEst.
Jan 2020
CompletionEst.
Feb 2021
Last update
Jul 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02640833
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 29, 2015
Start date
Jul 2016
Primary completion
Jan 2020 (estimated)
Completion
Feb 2021 (estimated)
Last update
Jul 26, 2016

Study contacts

John Hayslip, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvelisib

Start the discussion